Q-omics provides the consensus-scored SYT7 profile across patient tissues and cancer cell-line models. SYT7 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, SYT7 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, SYT7 protein abundance shows 33,099 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRP, KIRC, and GBM as cancer lineages where SYT7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SYT7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SYT7 survival associations across molecular data types. SYT7 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (6) and mass-spec protein abundance (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SYT7 RNA expression–survival associations across cancer types. High SYT7 expression shows unfavorable associations in KIRP, HNSC, MESO, KIRC, CESC and ACC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for SYT7 RNA expression.
This table summarizes SYT7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 9. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SYT7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SYT7 shows lower tumor expression in KIRC, KIRP and THCA and higher tumor expression in COAD, LUAD and BLCA. The KIRC box plot shows higher SYT7 RNA expression in normal versus tumor tissue (log2 FC = −3.360, t-test p < 0.001).
This table shows molecular features associated with SYT7 in patient tissues and cancer cell lines. In patient samples, SYT7 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, SYT7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BREAST.
